Ⅳ型胶原酶门脉灌注对兔血清TIMP-1的影响  

Effect of portal type Ⅳ collagenase administration on serologic TIMP-1 in liver cirrhosis rabbits

作　　者：于晓红 金博[2] 路平[3] 杨英祥[4] 

机构地区：[1]海军总医院干部病房综合科,北京100048 [2]海军总医院消化内科,北京100048 [3]海军总医院病理科,北京100048 [4]海军总医院肝胆外科,北京100048

出　　处：《胃肠病学和肝病学杂志》2012年第6期547-549,共3页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金资助项目(30670960)

摘　　要：目的通过四氯化碳(CCl4)皮下注射建立兔肝硬化动物模型,观察Ⅳ型胶原酶门脉灌注对血清基质金属蛋白酶组织抑制物-1(TIMP-1)表达的影响。方法新西兰大白兔,按0.23 mL/kg,皮下注射50%CCl4橄榄油制作肝硬化动物模型。12周后将形成肝硬化并门静脉插管成功的40只兔随机分为两组(组1、组2),每组20只。组1经门静脉注入0.1%Ⅳ型胶原酶1.5 mL,组2注入等量0.9%氯化钠,5次/周,共4周。对照组30只兔同样随机分为两组(组3、组4),每组15只,处理方法同前。4周后,将各组动物处死后留取肝脏组织,观察其病理学,并留取血清检测TIMP-1含量变化。结果门脉灌注0.1%Ⅳ型胶原酶可以显著减轻肝硬化动物肝纤维化程度,而血清TIMP-1含量显著增加。结论门脉灌注0.1%Ⅳ型胶原酶可显著降低肝纤维化程度,血清TIMP-1含量增加,可能与肝脏肝星状细胞激活有关。Objective To assess the effect of portal type IV collagenase administration on serologic TIMP-1 by estab- lishing liver cirrhosis models in rabbit through carbon tetraehloride subcutaneous injections. Methods New Zealand rabbits were injected 0.23 mL of 50% CC14/olive oil subcutaneously for 12 weeks to induce liver cirrhosis. After the portal delivery system （PDS） was established, 40 rabbits with established liver cirrhosis were divided randomly into 2 groups. The animals in group 1 （n = 20） were injected 1.5 mL of 0. 1% type IV eollagenase saline solution through PDS. The rabbits in group 2 （n = 20） received the same volume of 0.9% sodium chloride. The procedure was conduc- ted 5 times weekly for 4 weeks. As control group, 30 animals were divided into group 3 （n = 15） and group 4 （n = 15 ） which underwent the same procedure. All the animals were sacrificed at the end of the study, the serologic TIMP-1 was detected, the liver histologie examination was underwent. Results Portal administration of collagenase significantly at- tenuated liver cirrhosis and the serologic TIMP-1 was significantly elevated compared with the control group. Conclusion Collagenase portal administration significantly alleviated liver cirrhosis, while serum level of TIMP-I increased. This may attribute to the enhanced activation of hepatic stellate cells by eollagenase treatment.

关 键 词：肝硬化 胶原酶 门脉灌注 血清基质金属蛋白酶组织抑制物-1 

分 类 号：R575.2[医药卫生—消化系统]